Dong-E-E-Jiao Co.,Ltd. (000423.SZ) Bundle
Who is buying Dong-E-E-Jiao Co., Ltd. and why does it matter? As of December 2025 institutional investors control approximately 30% of the shares while retail holders account for about 36.2%, a split that underscores both professional confidence and broad public interest in the company's donkey-hide gelatin and TCM focus; the largest single investor, China Resources Company Limited, holds a commanding 33.8% stake, complemented by significant positions such as Hong Kong Exchanges and Clearing Limited at 9.44%, Zhong Ou Fund (3.23%), Harvest Fund (2.14%), UBS Asset Management (1.34%) and ICBC Credit Suisse (1.32%), and with the top 25 shareholders owning 61.3% overall this concentrated ownership shapes strategic direction and market signaling-factors made tangible by a market capitalization near CN¥31.1 billion, a trailing P/E of 18.74 and forward P/E of 16.58, even as the stock recently slid about 3.9% in a week; explore the investor mix, institutional influence, and market implications in the sections that follow.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Who Invests in Dong-E-E-Jiao Co.,Ltd. and Why?
Dong-E-E-Jiao attracts a mix of strategic, institutional and retail capital driven by its dominant position in traditional Chinese medicine (TCM) and steady commercial performance. The investor base reflects confidence in the company's product moat (donkey-hide gelatin), resilient demand in the health & wellness sector, and perceived defensive cash flows.- Institutional investors (other than the largest strategic holder) - approx. 30% of shares as of December 2025, signaling professional vote-of-confidence in governance and growth prospects.
- China Resources Company Limited - the single largest shareholder with 33.8% ownership, indicating strong strategic alignment and potential support for long-term stability and resource access.
- Retail investors - collectively hold about 36.2% of shares, showing broad public interest and consumer-investor alignment with the company's products and brand.
| Shareholder Category | Percentage of Shares | Implication |
|---|---|---|
| China Resources Company Limited (largest shareholder) | 33.8% | Strategic anchor investor; potential board influence and long-term support |
| Institutional investors (other) | 30.0% | Professional ownership providing market discipline, research coverage, and liquidity |
| Retail investors | 36.2% | High public engagement, brand loyalty reflected in shareholder base |
- Core product demand: Donkey-hide gelatin and related TCM offerings tap sustained consumer demand in aging and wellness demographics.
- Perceived defensive business model: Steady revenues and margins from established brands attract income-oriented and conservative investors.
- Strategic ownership: China Resources' 33.8% stake provides credibility, potential capital support and partnership synergies.
- Market positioning & growth: Consistent revenue growth and focused expansion in domestic and selective export channels draw growth-oriented funds.
- Investor mix benefits: Major institutional presence can stabilize share price and governance, while retail engagement boosts trading volume and brand advocacy.
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) Institutional Ownership and Major Shareholders of Dong-E-E-Jiao Co.,Ltd. (000423.SZ)
Dong-E-E-Jiao's share register is characterized by a concentrated institutional base with meaningful international participation and retail holdings providing liquidity. The top shareholders control a majority stake, while a mix of state-owned enterprise investment, domestic fund managers and foreign asset managers signal strategic, long-term and diversified investor interest.- Largest single shareholder: China Resources Company Limited - 33.8% (strategic/controlling stake).
- Significant exchange/market participant: Hong Kong Exchanges and Clearing Limited - 9.44%.
- Domestic asset managers: Zhong Ou Fund Management Co., Ltd. - 3.23%; Harvest Fund Management Co., Ltd. - 2.14%; ICBC Credit Suisse Fund Management Co., Ltd. - 1.32%.
- Foreign institutional presence: UBS Asset Management AG - 1.34%.
- Top 25 shareholders combined ownership: 61.3% - indicating concentrated control among major institutions and strategic investors.
- Remaining free float: held by general public/retail investors - providing on-market liquidity and retail participation.
| Shareholder | Stake (%) | Investor Type |
|---|---|---|
| China Resources Company Limited | 33.80 | State-owned strategic investor |
| Hong Kong Exchanges and Clearing Limited | 9.44 | Exchange/Institutional |
| Zhong Ou Fund Management Co., Ltd. | 3.23 | Domestic fund manager |
| Harvest Fund Management Co., Ltd. | 2.14 | Domestic fund manager |
| UBS Asset Management AG | 1.34 | Foreign asset manager |
| ICBC Credit Suisse Fund Management Co., Ltd. | 1.32 | Domestic fund manager |
| Top 25 shareholders (aggregate) | 61.30 | Aggregate institutional/strategic |
| General public / free float | 38.70 | Retail and other investors |
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Key Investors and Their Impact on Dong-E-E-Jiao Co.,Ltd.
China Resources Company Limited sits atop Dong-E-E-Jiao's shareholder register and is the dominant strategic shareholder. As of mid-2024 China Resources' stake is approximately 22-26% (majority single-block influence), giving it decisive voice over board composition, dividend policy and long-term strategic prioritization toward traditional medicine and upstream raw-material security. That concentrated ownership stabilizes corporate governance but also channels strategic decisions through a state-owned enterprise lens, encouraging conservative capital allocation and domestically focused expansion.- Approximate stake (mid-2024): 22-26%
- Impact: Board nominations, strategic alliances, procurement priorities for donkey-hide gelatin supply chain
- Approximate stake (mid-2024): 3-6%
- Impact: Emphasis on market disclosure, trading liquidity and investor relations
- Zhong Ou approximate stake: 1-3%
- Harvest approximate stake: 1-4%
- Impact: Quarterly rebalancing flows, shareholder proposals on capital allocation
- Approximate stake (mid-2024): ~1-3%
- Impact: Advice/pressure toward internationalization, earnings-quality transparency and ESG considerations
- Approximate stake (mid-2024): ~1-2%
- Impact: Reinforces domestic institutional demand, supports fixed-income-like shareholder expectations (steady dividends)
| Investor | Approx. Stake (mid-2024) | Primary Influence |
|---|---|---|
| China Resources Company Limited | 22-26% | Strategic control, board appointments, supply-chain priorities |
| Hong Kong Exchanges and Clearing Limited | 3-6% | Market stability, disclosure and liquidity focus |
| Zhong Ou Fund Management Co., Ltd. | 1-3% | Institutional demand, capital-allocation voting |
| Harvest Fund Management Co., Ltd. | 1-4% | Fund flow-driven positioning, dividend/capital policy influence |
| UBS Asset Management AG | ~1-3% | International perspective, ESG and global expansion guidance |
| ICBC Credit Suisse Fund Management Co., Ltd. | ~1-2% | Confidence signal, supports stable dividend expectations |
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) - Market Impact and Investor Sentiment
Dong-E-E-Jiao's stock action and company fundamentals have created a mixed but broadly constructive investor narrative. A recent week saw the share price slide 3.9%, a move that reverberated across both institutional and retail holders, but longer-term metrics and corporate actions help explain who is buying and why.
- Recent price move: -3.9% over a recent trading week, amplifying short-term volatility for both retail and institutional holders.
- Market capitalization: ≈ CN¥31.1 billion, reflecting meaningful scale within the healthcare / TCM sector.
- Valuation: trailing P/E = 18.74; forward P/E = 16.58 - indicating a moderate valuation band relative to growth prospects.
- Business momentum: consistent revenue growth and strategic positioning in traditional Chinese medicine (TCM) underpin positive sentiment.
- Corporate engagement: regular earnings presentations and shareholder reward policies (dividends/share buybacks or other rewards) support investor relations and confidence.
- Market thematic: rising global interest in natural health products and TCM enhances the stock's thematic appeal to thematic and ESG-adjacent investors.
| Metric | Value / Note |
|---|---|
| Market Capitalization | CN¥31.1 billion |
| Trailing P/E | 18.74 |
| Forward P/E | 16.58 |
| Recent Weekly Price Change | -3.9% |
| Investor Composition (approx.) | Institutional ~45% / Retail ~55% (indicative of strong retail participation) |
- Who's buying: value-oriented funds attracted by the reasonable P/E and stable earnings profile; thematic/healthcare funds seeking exposure to TCM and natural products; domestic retail investors drawn to brand recognition and shareholder rewards; selective long-only institutions eyeing steady revenue growth and defensive healthcare demand.
- Why they buy: moderate valuation vs. peers, durable demand for TCM products, clear investor communications, and the company's scale (CN¥31.1bn market cap) provide both growth and defensive characteristics.
For background on corporate history, ownership and how the company makes money, see Dong-E-E-Jiao Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money
Dong-E-E-Jiao Co.,Ltd. (000423.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.